Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Tolerability of Glatiramer Acetate

ClinicalTrials.gov ID: NCT01874145

Public ClinicalTrials.gov record NCT01874145. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis

Study identification

NCT ID
NCT01874145
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Enrollment
209 participants

Conditions and interventions

Interventions

  • GA 20 mg/mL Drug
  • GA 40 mg/mL Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2013
Primary completion
Mar 31, 2014
Completion
Apr 30, 2014
Last update posted
Jan 13, 2016

2013 – 2014

United States locations

U.S. sites
35
U.S. states
18
U.S. cities
34
Facility City State ZIP Site status
Teva Investigational Site 10706 Cullman Alabama
Teva Investigational Site 10719 Gilbert Arizona
Teva Investigational Site 10720 Phoenix Arizona
Teva Investigational Site 10727 Fresno California
Teva Investigational Site 10731 Long Beach California
Teva Investigational Site 10735 Newport Beach California
Teva Investigational Site 10712 Oceanside California
Teva Investigational Site 10708 Centennial Colorado
Teva Investigational Site 10715 Maitland Florida
Teva Investigational Site 10718 Pompano Beach Florida
Teva Investigational Site 10709 St. Petersburg Florida
Teva Investigational Site 10707 Tampa Florida
Teva Investigational Site 10711 Tampa Florida
Teva Investigational Site 10710 Northbrook Illinois
Teva Investigational Site 10734 Indianapolis Indiana
Teva Investigational Site 10732 Baltimore Maryland
Teva Investigational Site 10726 Great Falls Montana
Teva Investigational Site 10702 Henderson Nevada
Teva Investigational Site 10717 Patchogue New York
Teva Investigational Site 10723 Plainview New York
Teva Investigational Site 10716 Charlotte North Carolina
Teva Investigational Site 10724 Raleigh North Carolina
Teva Investigational Site 10721 Winston-Salem North Carolina
Teva Investigational Site 10733 Bellevue Ohio
Teva Investigational Site 10703 Columbus Ohio
Teva Investigational Site 10714 Dayton Ohio
Teva Investigational Site 10704 Uniontown Ohio
Teva Investigational Site 10725 East Providence Rhode Island
Teva Investigational Site 10736 Cordova Tennessee
Teva Investigational Site 10701 Franklin Tennessee
Teva Investigational Site 10728 Nashville Tennessee
Teva Investigational Site 10729 Mansfield Texas
Teva Investigational Site 10722 Round Rock Texas
Teva Investigational Site 10699 Salt Lake City Utah
Teva Investigational Site 10700 Roanoke Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01874145, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 13, 2016 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01874145 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →